Tagged as: Biosimilars News

AbbVie and Samsung Bioepis Announce Global Settlement of Adalimumab Disputes

Today, AbbVie and Samsung Bioepis announced that they have reached a global resolution of all intellectual property-related litigation relating to Samsung Bioepis’ biosimilar of Humira® (adalimumab), SB5, clearing the way for its commercialization in all approved markets worldwide.  SB5 has already received marketing authorization from the European Commission (EC) as…

Read More

Recent Biosimilar Industry Coverage

A number of media sources have covered new developments in the biosimilars space.  Here is a round-up of some highlights from this month. Reuters reports that biosimilars, including biosimilar versions of Rituxan and Herceptin, have begun to capture a large portion of the British biosimilar market, whereas approvals and adoptions…

Read More

FDA Commissioner Gottlieb Gives Speech on Biosimilars

Earlier today, FDA Commissioner Scott Gottlieb, MD, gave a speech focusing on biosimilars at America’s Health Insurance Plans’ National Health Policy Conference in Washington, D.C.  In his speech, Commissioner Gottlieb highlighted a 2017 study by QuintilesIMS that observed significant cost savings and dramatically expanding patient access in the EU from biosimilars…

Read More